The second quarter of 2019 has ended with major acquisitions in pharma and biotech industry. Moving with the latest acquisition of Allergan for $63B by AbbVie focusing on to generate revenue with addition of Allergan's medical aesthetics and ophthalmology portfolio. Prior to that, Pfizer acquired Array Biopharma for $11.4B to expand its oncology portfolio. Some…
